OSE On The Up As Phase III For Cancer Vaccine Is Prepped
French Biotech Trumpets Tedopi Potential In Lung Cancer
Executive Summary
OSE’s late-stage ambitions for Tedopi were stalled by the pandemic but the Nantes-based firm has now requested a meeting with the US FDA to get the Phase III program for the anticancer vaccine back on track.